Rates of type 2 diabetes in the U.S. pediatric population are rising ([@B1],[@B2]). Because type 2 diabetes can be asymptomatic at diagnosis and requires tight glycemic, blood pressure, and lipid control to delay the onset of microvascular and macrovascular complications, screening for type 2 diabetes in children is endorsed by the American Diabetes Association (ADA) and the American Academy of Pediatrics ([@B3],[@B4]). There is also increasing interest in screening for prediabetes in the pediatric population ([@B5],[@B6]), given its increasing prevalence ([@B7]) and the documented link between prediabetes in childhood and development of diabetes in young adulthood ([@B8]).

The ADA guidelines ([@B3]) recommend that children with a BMI ≥85th percentile for age and sex and additional risk factors should be screened every 2 years starting at age 10 years or at onset of puberty and that either a fasting plasma glucose (FPG) or a 2-h glucose tolerance test be performed. However, these recommendations were based on expert opinion and were not evidence based, as acknowledged by the ADA in its Position Statement.

Both FPG and 2-h postload glucose have traditionally been used as the gold standard tests for diagnosing diabetes, but both tests require that the individual be fasting, which is an important barrier to screening. Studies have found that only a minority (4--21%) of pediatric providers in the primary care setting have screening practices consistent with the ADA guidelines ([@B9],[@B10]) and instead use nonfasting tests, such as HbA~1c~, random glucose, or urinalysis.

Furthermore, in 2009, the screening and diagnosis landscape changed when an international expert committee of individuals from the ADA and their international counterparts recommended that HbA~1c~ be exclusively used for the diagnosis of diabetes with eventual phase out of additional glucose measurements such as FPG and the 2-h postload glucose ([@B11]).

Despite the frequent use of nonfasting tests by physicians in clinical practice and the recent guideline advocating HbA~1c~ as a diagnostic test for diabetes among children, there is a critical lack of data about the performance of nonfasting tests in children. Therefore, the objective of our study was to assess the test performance of nonfasting screening tests, including HbA~1c~, urinalysis, fructosamine, a nonfasting 1-h glucose challenge test (1-h GCT), and a random blood glucose for identifying adolescents aged 10--17 years with dysglycemia. Empiric information about test performance for nonfasting diabetes tests is critical for the development of evidence-based screening recommendations for prediabetes and diabetes in overweight and obese children.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Our study population consisted of a convenience sample of overweight or obese adolescents aged 10--17 years without known diabetes. The majority of children were recruited from pediatric primary care clinics (85%) with a smaller fraction (15%) from pediatric specialty clinics in the southeast Michigan area. Patients and families were recruited by research assistants in the clinic or responded to flyers posted in pediatric clinics and received an incentive for participating in the study. We excluded those who were pregnant and those who were on medications known to affect glucose metabolism.

Children came in for two visits to the Michigan Clinical Research Unit, where a history and physical exam were performed. For the first visit, they had a formal 2-h oral glucose tolerance test (OGTT) performed. They were fasting for a minimum of 12 h and had an intravenous catheter placed. Blood was drawn at baseline and every 30 min up to 2 h following a glucose ingestion of 1.75 g/kg to a maximum of 75 g. Testing was also conducted for HbA~1c~ and fructosamine. Within 1--3 weeks, participants returned for a second visit in a nonfasting state. They had a random glucose test (glucose measured in a nonfasting state), a 1-h GCT (glucose measured 1 h after ingestion of 50 g of glucola in a nonfasting state), and urinalysis (measured 1 h after ingestion of 50 g glucola). We elected to use a uniform 50-g challenge (which was well tolerated by the children), given that it would be difficult for primary care providers to calculate weight-specific doses. Visit one was generally conducted in the morning, with mean time of administration of glucola 9:34 [a.m.]{.smallcaps}, and visit two was generally conducted in the afternoon, with random plasma glucose (PG) drawn at a mean time of 1:23 [p.m.]{.smallcaps} The majority of families did not have access to their results until after visit two; therefore, it is unlikely that the children and their families were sensitized to the issue of diabetes.

Glucose was measured using the glucose hexokinase method, and HbA~1c~ was measured using an NGSP-certified assay in whole blood (Pointe Scientific) using anti-human HbA~1c~ monoclonal antibody. Glucose, fructosamine, and HbA~1c~ were all measured using the Cobas Mira Plus Chemistry Analyzer. Urine dipstick was performed using Chemstrip 10 strips manufactured by Roche. Laboratory measurements were performed by the Michigan Diabetes Research and Training Center Core Laboratories.

Study definitions {#s6}
-----------------

Measured height and weight were converted to BMI percentiles according to the 2000 Centers for Disease Control and Prevention growth curves ([@B12]). Overweight was defined as an age-, sex-, and race-specific BMI ≥85th and \<95th percentile, and obesity was similarly defined as a BMI ≥95th percentile. We elected to use definitions of prediabetes and diabetes based on the FPG and the 2-h PG. We acknowledge limitations of these definitions, given studies which have shown low concordance ([@B13]) and lack of reproducibility ([@B14],[@B15]). However, these definitions have traditionally been used throughout the pediatric literature ([@B16]--[@B18]), which is important for comparison of our data with previous literature. Furthermore, these tests were the ADA-recommended gold standard tests prior to 2010 ([@B19]). With the 2010 revised guidelines ([@B20]), individuals can still be classified as having prediabetes or diabetes according to these tests, even if they are not recommended as first-line tests.

Based on the OGTT, considered the gold standard test, normal glucose metabolism was defined as a 2-h postload glucose level of \<140 mg/dL and an FPG of \<100 mg/dL. Prediabetes was defined as either impaired glucose tolerance (IGT) (2-h postload glucose ≥140 and \<200 mg/dL) or impaired fasting glucose (IFG) (FPG ≥100 and \<126 mg/dL). Diabetes was defined as a 2-h postload glucose ≥200 mg/dL or FPG ≥126 mg/dL ([@B19]). Because of the low number of children with diabetes (*n* = 3), we created a combined outcome of dysglycemia (prediabetes or diabetes) (*n* = 102). Any evidence of glucose (trace or above) was classified as a positive urine dipstick result. In sensitivity analyses, we assessed the degree to which the nonfasting tests predicted IGT and IFG separately, and we provide results of testing for prediabetes alone, excluding those from the three individuals with diabetes ([Supplementary Fig. 1*C*](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0827/-/DC1)).

We assessed sensitivity, specificity, positive likelihood ratio, and positive and negative predictive values at various thresholds of each test, with the exception of the urine dipstick test, for which the result was either positive or negative. Positive likelihood ratios represent the ratio of sensitivity to 1-specificity; positive predictive value represents the probability of having the disease given a positive test result, and negative predictive value represents the probability of not having the disease given a negative test result. We then used receiver operating characteristic (ROC) analysis, which assesses the trade-offs between sensitivity and specificity at various test cutoffs or thresholds for each of the four remaining nonfasting tests. We tested the homogeneity of ROC areas across the nonfasting tests.

Previous studies in adults have found that the number of hours since the last meal (postprandial time) can impact nonfasting test performance ([@B21]). Therefore, we also assessed test performance in children by postprandial time (\<2 h and ≥2 h) and by time of day ([a.m.]{.smallcaps} vs. [p.m.]{.smallcaps}) for random glucose and 1-h GCT.

The prevalence of type 2 diabetes in children is low ([@B22]). For example, the recent SEARCH for Diabetes in Youth study used gold standard methods for defining type 2 diabetes and reported a prevalence of 0.04% among U.S. adolescents aged 10--19 years in 2001 ([@B23]). Therefore, our sample size calculations were based on the combined outcome of prediabetes and diabetes. Our goal was a sample size of 250, assuming a 35% prevalence of prediabetes in the population, a sensitivity of 65%, and a width of 20% for a two-sided 95% CI. Statistical analyses were performed using Stata 10.0 (Stata-Corp, College Station, TX). Sample sizes stratified by race and sex were too small to make reasonable conclusions. This study was approved by the University of Michigan institutional review board.

RESULTS {#s7}
=======

[Table 1](#T1){ref-type="table"} shows demographic characteristics of the 254 children in the study. There were slightly more female than male subjects, and close to one-third of the population was black. There was a higher proportion of obese children in the sample compared with overweight children. Of the population, 39% had prediabetes, and only 1.2% of children were classified as having diabetes. Although there was a higher prevalence of prediabetes in blacks (46%) compared with whites (36%) and male subjects (44.6%) compared with female subjects (36.1%), these comparisons were not statistically significant. The majority of children in the study were pubertal, regardless of glucose tolerance status.

###### 

Characteristics of the study population

                                                                      Overall population   Normal glucose tolerance   IFG only     IGT only     IFG and IGT   Diabetes
  ------------------------------------------------------------------- -------------------- -------------------------- ------------ ------------ ------------- ------------
  *n*                                                                 254                  152                        46           36           17            3
  Age (years), mean (SD)                                              13.6 (2.1)           13.6 (2.2)                 14.0 (1.9)   13.5 (2.0)   13.0 (1.9)    12.1 (2.2)
  Sex                                                                                                                                                         
   Female                                                             52.4 (133)           55.9 (85)                  45.7 (21)    55.6 (20)    35.3 (6)      33.3 (1)
   Male                                                               47.6 (121)           44.1 (67)                  54.3 (25)    44.4 (16)    64.7 (11)     66.7 (2)
  Race                                                                                                                                                        
   White                                                              59.1 (150)           63.2 (96)                  47.8 (22)    50.0 (18)    70.6 (12)     66.7 (2)
   Black                                                              29.9 (76)            27.0 (41)                  45.7 (21)    33.3 (12)    5.9 (1)       33.3 (1)
   Other                                                              11.0 (28)            9.8 (15)                   6.5 (3)      16.7 (6)     23.5 (4)      ---
  Weight status                                                                                                                                               
   Overweight (BMI ≥85th percentile and \<95th percentile)            21.6 (55)            25.7 (39)                  19.6 (9)     8.3 (3)      17.7 (3)      33.3 (1)
   Obese (BMI ≥95th percentile)                                       78.4 (199)           74.3 (113)                 80.4 (37)    91.7 (33)    82.3 (14)     66.7 (2)
  Family history of type 2 diabetes[\*](#t1n1){ref-type="table-fn"}                                                                                           
   Yes                                                                76.2 (166)           70.5 (93)                  84.2 (32)    81.3 (26)    92.9 (13)     ---
   No                                                                 23.8 (52)            29.5 (39)                  15.8 (6)     18.7 (6)     7.1 (1)       100.0 (2)
  Tanner stage[\*\*](#t1n2){ref-type="table-fn"}                                                                                                              
   Median (range)                                                     4 (1--5)             4 (1--5)                   4 (1--5)     4 (1--5)     3 (1--5)      1.5 (1--2)
   Prepubertal                                                        6.6 (13)             6.8 (8)                    2.9 (1)      6.7 (2)      8.3 (1)       50.0 (1)
   Pubertal (Tanner stage 2 or higher)                                93.4 (184)           93.2 (110)                 97.1 (34)    93.3 (28)    91.7 (11)     50.0 (1)

Data are % (*n*) unless otherwise noted.

\*For those with self-reported family history.

\*\*For those with self-reported pubertal measures.

[Table 2](#T2){ref-type="table"} shows performance results of the five different nonfasting tests for identifying children with dysglycemia. Urine dipstick, for which there was only one threshold (positive vs. negative), had a very low sensitivity despite a high specificity. For the other tests, higher test thresholds resulted in a lower sensitivity and a higher specificity and lower test thresholds in a higher sensitivity and a lower specificity.

###### 

Test characteristics of HbA~1c~, urinalysis, fructosamine, random glucose, and 1-h GCT for predicting dysglycemia (prediabetes or diabetes)

  Threshold                                                     Sensitivity (%)   Specificity (%)   Positive likelihood ratio   Positive predictive value (%)   Negative predictive value (%)
  ------------------------------------------------------------- ----------------- ----------------- --------------------------- ------------------------------- -------------------------------
  Urinalysis (*n* = 218)                                                                                                                                        
   Positive                                                     2                 97                0.75                        34                              59
  HbA~1c~ (%) (AUC 0.54 \[95% CI 0.47--0.61\]; *n* = 254)                                                                                                       
   4.4                                                          100               0                 1.00                        40                              
   4.7                                                          99                2                 1.01                        41                              75
   5.0                                                          93                9                 1.03                        41                              67
   5.3                                                          70                36                1.08                        42                              63
   5.5                                                          45                57                1.04                        41                              60
   5.7                                                          32                74                1.23                        45                              62
   6.0                                                          15                92                1.86                        56                              62
   6.5                                                          7                 98                3.48                        70                              61
   7.0                                                          2                 100                                           100                             60
  Fructosamine (mmol/L) (AUC 0.55 \[0.47--0.63\]; *n* = 222)                                                                                                    
   0                                                            100               0                 1.00                        40                              
   1.25                                                         71                29                0.99                        40                              59
   1.45                                                         47                60                1.17                        44                              63
   1.65                                                         24                88                2.08                        58                              63
   1.85                                                         12                99                7.91                        84                              62
   2.05                                                         6                 100                                           100                             61
  Random glucose (mg/dL) (AUC 0.66 \[0.60--0.73\]; *n* = 243)                                                                                                   
   50                                                           100               0                 1.00                        40                              
   60                                                           99                1                 1.00                        40                              50
   70                                                           98                5                 1.03                        41                              78
   80                                                           97                17                1.17                        44                              89
   90                                                           87                33                1.30                        47                              79
   100                                                          55                67                1.66                        53                              69
   110                                                          30                88                2.38                        62                              65
   120                                                          14                96                3.45                        70                              62
   130                                                          7                 99                5.18                        78                              61
   140                                                          3                 99                4.44                        75                              60
  1-h OGTT (mg/dL) (AUC 0.68 \[0.61--0.74\]; *n* = 241)                                                                                                         
   60                                                           100               0                 1.00                        40                              
   70                                                           99                2                 1.01                        41                              75
   80                                                           96                11                1.08                        42                              80
   90                                                           90                25                1.20                        45                              78
   100                                                          77                42                1.34                        48                              73
   110                                                          63                63                1.68                        53                              71
   120                                                          44                81                2.28                        61                              68
   130                                                          31                92                4.05                        73                              66
   140                                                          21                92                2.70                        65                              63
   150                                                          13                97                3.86                        72                              62
   160                                                          9                 98                4.45                        75                              62
   170                                                          4                 100                                           100                             61

[Figure 1*A*--*D*](#F1){ref-type="fig"} displays ROC curves at various cutoffs for each of the four remaining nonfasting tests. Discrimination was equally poor for HbA~1c~ and fructosamine, as indicated by relatively low likelihood ratios across thresholds and low values for area under the curve (AUC). In contrast, random glucose and 1-h GCT had levels of test discrimination closer to an acceptable range. Compared with HbA~1c~, there was no significant difference in AUC for fructosamine, but AUC was significantly higher for both random glucose (*P* = 0.01) and 1-h GCT (*P* \< 0.01). We did not find any differences in test performance by postprandial time or by time of day ([a.m.]{.smallcaps} vs. [p.m.]{.smallcaps}) for the 1-h GCT or the random glucose (data not shown).

![ROC curve for predicting dysglycemia (prediabetes or diabetes) at various thresholds of nonfasting tests. *A*: HbA~1c~ (AUC 0.54 \[95% CI 0.47--0.61\]; *n* = 254). *B*: Fructosamine (AUC 0.55 \[0.47--0.63\]; *n* = 222). *C*: Random glucose (AUC 0.66 \[0.60--0.73\]; *n* = 243). *D*: 1-h GCT (AUC 0.68 \[0.61--0.74\]; *n* = 241).](2597fig1){#F1}

ROC curves were also created for identifying individuals with IGT and IFG as separate outcomes ([Supplementary Fig. 1*A* and *B*](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0827/-/DC1)). Although AUC appeared to be quite similar for most tests, AUC for the 1-h GCT was substantially higher for predicting IGT (0.72) compared with IFG (0.58), which is consistent with the fact that both types of tests are stimulated glucose tests. Test performance was slightly lower when only those with prediabetes were included in the analysis ([Supplementary Fig. 1*C*](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0827/-/DC1)).

CONCLUSIONS {#s8}
===========

We systematically evaluated a variety of nonfasting screening tests used in the clinical setting for identifying dysglycemia in a population of overweight and obese adolescents and found reasonable test performance for the 1-h GCT and the random glucose. In contrast, test performance for HbA~1c~, fructosamine, and urinalysis was poor. Our findings have direct relevance for future recommendations for screening and diagnosis of dysglycemia among overweight and obese children and adolescents.

The poor test performance of HbA~1c~ is notable given recent changes in diagnostic guidelines for prediabetes and diabetes ([@B11]), which advocate the use of HbA~1c~ for identifying children and adults with diabetes (HbA~1c~ ≥6.5%) and prediabetes (HbA~1c~ 5.7--6.4%). We found that HbA~1c~ had less than acceptable test performance for children with dysglycemia. Although the majority of patients in our study had prediabetes, two of three children with diabetes would have been missed using the ADA recommendation of 6.5%, with HbA~1c~ levels of 5.1 and 5.2%.

Our findings are consistent with recent studies of HbA~1c~ test performance in children. Using a nationally representative sample from National Health and Nutrition Examination Survey (NHANES) 1999--2006 ([@B24]), we found that an HbA~1c~ threshold of 6.0% had low sensitivity for identifying overweight or obese children with prediabetes; sensitivity was 1.1% for identifying children with IFG (based on an FPG ≥100 mg/dL) and 0% for identifying children with IGT (based on a 2-h postload glucose ≥140 mg/dL), despite having high specificity for both outcomes (99%). In addition, the AUC for HbA~1c~ was relatively low at 0.61 for predicting IFG and 0.53 for predicting IGT. Another study of a large cohort of obese children has also reported lower sensitivity for HbA~1c~ ([@B25]). In contrast, adult studies have shown higher sensitivities for dysglycemia in the range of (20--25%) and higher levels of discrimination ([@B26]).

To our knowledge, the HbA~1c~ guidelines have yet to be reviewed or endorsed by pediatric organizations such as the American Academy of Pediatrics. If the guidelines were to be endorsed by these organizations, this would most likely result in increased uptake of the test by providers, which could potentially lead to a significant proportion of missed cases of prediabetes and diabetes in the pediatric population.

Either the nonfasting 1-h GCT or the random glucose represent promising screening tests for use in the pediatric primary care setting, as these are tests that clinicians can easily order the same day of the visit. This would exclude a substantial proportion of children who would have to return for testing, and subsequently, only the subset of children with glucose levels surpassing specified thresholds of either nonfasting test would then have to undergo more formal testing with an FPG or a 2-h OGTT to confirm the diagnosis. Possible test thresholds to consider for the pediatric population for the 1-h GCT include cutoffs of 110 or 120 mg/dL, which would result in sensitivities of 63 and 44% and false-positive rates of 37 and 19%, respectively. Comparable thresholds using random glucose levels could include cutoffs of 100 or 110 mg/dL, which would result in sensitivities of 55 and 30% and false-positive rates of 33 and 12%, respectively.

Studies in adults have also found random glucose and 1-h GCT to be promising tests to use for screening for prediabetes and diabetes in adults. The Screening for Impaired Glucose Tolerance Study evaluated test performance of random glucose and 1-h GCT and found that both tests showed reasonable discrimination for identifying dysglycemia, with estimates of AUC of 0.72 for random PG and 0.82 for 1-h GCT, although their definition of dysglycemia was slightly different (IGT, IFG ≥110 mg/dL, or diabetes) ([@B21],[@B27]). Similarly, studies in pregnant women to screen for gestational diabetes mellitus have reported reasonable test performance, hence, the use of this test as an initial screen to determine which women need full 3-h OGTT tests to look for gestational diabetes mellitus ([@B28]).

We found a very low sensitivity of urine dipstick for detecting dysglycemia, despite the fact that it was measured 1 h after ingestion of 50 g glucola. Sensitivity was even lower than for adult studies, which have reported sensitivities ranging from 18 to 64% ([@B29]). Because the renal glucose threshold is \~180 mg/dL, the sensitivity of this test for detecting diabetes would be expected to be better for diabetes than for prediabetes. However, in our study urine dipstick detected only two cases of prediabetes and failed to identify any of the three individuals with diabetes. Urinalysis is reportedly still being used for diabetes screening in the pediatric primary care setting ([@B9]); therefore, providers should perhaps be dissuaded from using this test in clinical practice.

We found no differences in test performance based on postprandial time or time of day, which contrasts with studies in adults that have reported improvements in test performance for random blood glucose with a longer postprandial period (\>2 h) prior to the test ([@B21]). We also assessed test performance for predicting IFG and IGT as separate outcomes. Regardless of the outcome measure, test performance remained poor for HbA~1c~ and fructosamine. However, when using IGT, we found significant improvements in test performance for the 1-h GCT. Both IGT and IFG predict risk for developing diabetes, but because of convenience previous screening recommendations have prioritized the use of FPG. Studies have shown that a stimulated glucose is a better predictor than FPG of progression from IGT to diabetes ([@B30]). Furthermore, FPG will often miss cases of IGT and diabetes ([@B31],[@B32]), further lending support for the use of random glucose or the 1-h GCT test in clinical practice.

Strengths of our study include the systematic evaluation of the performance of nonfasting tests in a pediatric population, the use of a gold standard 2-h OGTT for classifying children with dysglycemia, a reasonable study sample size, and the substantial proportion of minority children who were included in the study. We also acknowledge limitations of our study. According to the ADA, two positive tests are required to make a diagnosis of prediabetes or diabetes ([@B20]), and studies have reported a lack of reproducibility of the diagnosis of prediabetes using the 2-h OGTT in children ([@B15]). Therefore, children in our cohort with 2-h postload glucose levels \>200 mg/dL may not have been classified as having diabetes if a second test had been performed, which could result in improvements in test performance. Although it would have been ideal to perform two 2-h OGTTs, we elected to perform one given the additional burden on participants. Furthermore, clinical research studies of adults, including the Diabetes Prevention Project ([@B33]), or the Screening for Impaired Glucose Tolerance Study ([@B27]), have classified participants' glucose status using just one test.

With the new guidelines, HbA~1c~ would now be considered the gold standard for diabetes, but studies have demonstrated significant differences in diabetes and prediabetes prevalence depending on the definition of diabetes used (FPG vs. 2-h postload glucose vs. HbA~1c~) ([@B34]). Although it may be logical to use a chronic measure of hyperglycemia such as HbA~1c~ rather than an acute measure such as glucose, longitudinal studies in children are needed to understand which tests are most predictive of later development of diabetes. We elected to compare the nonfasting tests against the definitions of diabetes that have been historically used in the pediatric literature for purposes of comparability with other pediatric studies.

Our population was a convenience sample of overweight and obese children from southeast Michigan rather than a systematic sample from a well-defined target population. Although we had adequate representation of black and white children, there were no Hispanic children in the sample. Furthermore, given the sample size, we did not have the power to assess test performance according to each Tanner stage. Therefore, generalizations must be made accordingly. We had to power our study to the outcome of dysglycemia given the low prevalence of childhood diabetes. However, we note that this is reflective of the epidemiology of type 2 diabetes in the U.S., which still has a very low prevalence in the adolescent population (0.02%), particularly compared with adults ([@B23]). The ADA screening guidelines were established in 2000 ([@B3]) based on reports of dramatic increases in type 2 diabetes among adolescents, but subsequent population-based epidemiologic studies have not revealed a large burden of childhood type 2 diabetes. Identification of children with prediabetes, which has a much higher burden in the pediatric population, could be considered a useful by-product of diabetes screening, which would provide the opportunity for directing targeted interventions at children at highest risk for developing diabetes.

Because of the high burden of childhood obesity, the CDC estimates that approximately 2.5 million children in the U.S. potentially qualify for diabetes screening based on the ADA screening guidelines ([@B35]), highlighting the need for effective and practical strategies for screening. Random glucose and particularly 1-h GCT, given its possible greater predictive capacity for incident diabetes ([@B36]), represent promising screening tests for use in the pediatric primary care setting. Future studies are needed to assess the feasibility, acceptability, and cost-effectiveness of these alternative screening strategies compared with current recommendations and to assess the impact of systematic prediabetes and diabetes screening on pediatric health outcomes.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0827/-/DC1>.
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